How I Diagnose Non-thalassemic Microcytic Anemias

Seminars in Hematology

Volumn 52, Issue 4, 2015, Pages 270-278

  Bruno, Mariasole ^a,b,c   De Falco, Luigia ^a,b   Iolascon, Achille ^a,b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^c UNIVERSITY OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; HEMOPROTEIN; HEPCIDIN; IRON; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; DEOXYHEMOGLOBIN;

ALAS2 GENE; ATAXIA; CONGENITAL ERYTHROPOIETIC PORPHYRIA; ERYTHROCYTE VOLUME; GENE; GENE MUTATION; GENETIC DISORDER; HEREDITARY ACERULOPLASMINEMIA; HEREDITARY HYPOTRANSFERRINEMIA; HUMAN; IRON DEFICIENCY ANEMIA; IRON METABOLISM; MASS SPECTROMETRY; MICROCYTIC ANEMIA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN METABOLISM; REVIEW; SIDEROBLASTIC ANEMIA; STEAP3 GENE; X LINKED SIDEROBLASTIC ANEMIA; ANEMIA, HYPOCHROMIC; ANEMIA, IRON-DEFICIENCY; ANIMAL; DIFFERENTIAL DIAGNOSIS; METABOLISM;

ANEMIA, HYPOCHROMIC; ANEMIA, IRON-DEFICIENCY; ANIMALS; DIAGNOSIS, DIFFERENTIAL; HEMOGLOBINS; HUMANS; IRON;

EID: 84941906000     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2015.05.002     Document Type: Review

References (60)

1. Van Vranken M. Evaluation of microcytosis. Am Fam Physician 2010, 82(9):1117-1122.
2. Camaschella C. How I manage patients with atypical microcytic anaemia. Br J Haematol 2013, 160(1):12-24.
3. Ghosh K., Colah R., Manglani M., et al. Guidelines for screening, diagnosis and management of hemoglobinopathies. Indian J Hum Genet 2014, 20(2):101-119.
4. Gulec S., Anderson G.J., Collins J.F. Mechanistic and regulatory aspects of intestinal iron absorption. Am J Physiol Gastrointest Liver Physiol 2014, 307(4):G397-G409.
5. Latunde-Dada G.O., Simpson R.J., McKie A.T. Duodenal cytochrome B expression stimulates iron uptake by human intestinal epithelial cells. J Nutr 2008, 138(6):991-995.
6. Fleming M.D., Trenor CC, Su M.A., et al. Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene. Nature Genet 1997, 16:383-386.
7. Roeser H.P., Lee G.R., Nacht S., Cartwright G.E. The role of ceruloplasmin in iron metabolism. J Clin Invest 1970, 49:2408-2417.
8. Iolascon A., De Falco L. Mutations in the gene encoding DMT1: clinical presentation and treatment. Semin Hematol 2009, 46(4):358-370.
9. Ferreira G.C., Gong J. 5-Aminolevulinate synthase and the first step of heme biosynthesis. J Bioenerg Biomembr 1995, 27:151-159.
10. Krishnamurthy P., Ross D.D., Nakanishi T., et al. The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J Biol Chem 2004, 279:24218-24225.
11. Ganz T., Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta 2012, 1823:1434-1443.
12. De Domenico I., McVey Ward D., Kaplan J. Regulation of iron acquisition and storage: consequences for iron-linked disorders. Nat Rev Mol Cell Biol 2008, 9:72-81.
13. Babitt J.L., Huang F.W., Wrighting D.M., Xia Y., Sidis Y., Samad T.A. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet 2006, 38:531-539.
14. Kautz L., Jung G., Valore E.V., Rivella S., Nemeth E., Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet 2014, 46:678-684.
15. Reeves J.D., Yip R., Kiley V.A., Dallman P.R. Iron deficiency in infants: the influence of mild antecedent infection. J Pediatr 1984, 105(6):874-879.
16. Mustalahti K., Catassi C., Reunanen A., et al. For Coeliac EU Cluster, Project Epidemiology. The prevalence of celiac disease in Europe: results of a centralized, international mass screening project. Ann Med 2010, 42(8):587-595.
17. Weiss G., Goodnough L.T. Anemia of chronic disease. N Engl J Med 2005, 352:1011-1023.
18. Pinevich A.J., Petersen J. Erythropoietin therapy in patients with chronic renal failure. West J Med 1992, 157(2):154-157.
19. Rahim F. Microcytic hypochromic anemia patients with thalassemia: genotyping approach. Indian J Med Sci 2009, 63(3):101-108.
20. Camaschella C. Recent advances in the understanding of inherited sideroblastic anaemia. Br J Haematol 2008, 143:27-38.
21. Ducamp S., Kannengiesser C., Touati M., et al. Sideroblastic anemia: molecular analysis of the ALAS2 gene in a series of 29 probands and functional studies of 10 missense mutations. Hum Mutat 2011, 32:590-597.
22. Interaction between succinyl CoA synthetase and the heme-biosynthetic enzyme ALAS-E is disrupted in sideroblastic anemia. J Clin Invest 2000, 105:757-764.
23. Cazzola M., Invernizzi R., Bergamaschi G., et al. Mitochondrial ferritin expression in erythroid cells from patients with sideroblastic anemia. Blood 2003, 101:1996-2000.
24. Bekri S, Kispal G, Lange H, et al. Human ABC7 transporter: gene structure and mutation causing X-linked sideroblastic anemia with ataxia with disruption of cytosolic iron-sulfur protein maturation. Blood. 2000;96:3256e64.
25. D' Hooghe M., Selleslag D., Mortier G., et al. X-linked sideroblastic anemia and ataxia: a new family with identification of a fourth ABCB7 gene mutation. Eur J Paediatr Neurol 2012, 16(6):730-735.
26. Wingert R.A., Galloway J.L., Barut B., et al. Deficiency of glutaredoxin 5 reveals Fe-S clusters are required for vertebrate haem synthesis. Nature 2005, 436:1035-1039.
27. Liu G., Guo S., Anderson G.J., Camaschella C., Han B., Nie G. Heterozygous missense mutations in the GLRX5 gene cause sideroblastic anemia in a Chinese patient. Blood 2014, 124(17):2750-2751.
28. Guernsey DL, Jiang H, Campagna DR, Evans SC, Ferguson M, Kellogg MD. Mutations in mitochondrial carrier family gene SLC25A38 cause non syndromic autosomal recessive congenital sideroblastic anemia. Nat Genet. 2009;41(6):651-3.
29. Chakraborty P.K., et al. Mutations in TRNT1 cause congenital sideroblastic anemia with immunodeficiency, fevers, and developmental delay (SIFD). Blood 2014, 124(18):2867-2871.
30. Aslan D., Crain K., Beutler E. A new case of human atransferrinemia with a previously undescribed mutation in the transferrin gene. Acta Haematol 2007, 118:244-247.
31. Beutler E., Gelbart T., Lee P., Trevino R., Fernandez M.A., Fairbanks V.F. Molecular characterization of a case of atransferrinemia. Blood 2000, 96:4071-4074.
32. Harris Z.L., Takahashi Y., Miyajima H., Serizawa M., MacGillivray R.T., Gitlin J.D. Aceruloplasminemia: molecular characterization of this disorder of iron metabolism. Proc Natl Acad Sci U S A 1995, 92:2539-2543.
33. Ogimoto M., Anzai K., Takenoshita H., et al. Criteria for early identification of aceruloplasminemia. Intern Med 2011, 50(13):1415-1418.
34. Perez-Aguilar F., Burguera J.A., Benlloch S., Berenguer M., Rayon J.M. Aceruloplasminemia in an asymptomatic patient with a new mutation. Diagnosis and family genetic analysis. J Hepatol 2005, 42:947-949.
35. Sassa S. Modern diagnosis and management of the porphyrias. Br J Haematol 2006, 135:281-292.
36. Guo S., Wang L., Li X., Nie G., Li M., Han B. Identification of a novel UROS mutation in a Chinese patient affected by congenital erythropoietic porphyria. Blood Cells Mol Dis 2014, 52(1):57-58.
37. Singh S., Khanna N., Kumar L. Bone marrow transplantation improves symptoms of congenital erythropoietic porphyria even when done post puberty. Indian J Dermatol Venereol Leprol 2012, 78:108-111.
38. Di Pierro E., Russo R., Karakas Z., et al. Congenital erythropoietic porphyria linked to GATA1-R216W mutation: challenges for diagnosis. Eur J Haematol 2015, 94(6):491-497.
39. Phillips J.D., Steensma D.P., Pulsipher M.A., Spangrude G.J., Kushner J.P. Congenital erythropoietic porphyria due to a mutation in GATA1: the first trans-acting mutation causative for a human porphyria. Blood 2007, 109(6):2618-2621.
40. Balwani M., Doheny D., Bishop D.F., et al. Loss of function ferrochelatase and gain-of-function erythroid-specific 5-aminolevulinate synthase mutations causing erythropoietic protoporphyria and x-linked protoporphyria in North American patients reveal novel mutations and a high prevalence of X-linked protoporphyria. Mol Med 2013, 19:26-35.
41. Crooks D.R., Ghosh M.C., Haller R.G., Tong W.H., Rouault T.A. Posttranslational stability of the heme biosynthetic enzyme ferrochelatase is dependent on iron availability and intact iron-sulfur cluster assembly machinery. Blood 2010, 115:860-869.
42. Holme S.A., Worwood M., Anstey A.V., Elder G.H. Badminton MN. Erythropoiesis and iron metabolism in dominant erythropoietic protoporphyria. Blood 2007, 110(12):4108-4110.
43. Lyoumi S., Abitbol M., Andrieu V., et al. Increased plasma transferrin, altered body iron distribution, and microcytic hypochromic anemia in ferrochelatase-deficient mice. Blood 2007, 109(2):811-818.
44. Gunshin H., Fujiwara Y., Custodio A.O., Direnzo C., Robine S., Andrews N.C. Slc11a2 is required for intestinal iron absorption and erythropoiesis but dispensable in placenta and liver. J Clin Invest 2005, 115(5):1258-1266.
45. Mims M.P., Guan Y., Pospisilova D., Priwitzerova M., Indrak K., Ponka P. Identification of a human mutation of DMT1 in a patient with microcytic anemia and iron overload. Blood 2005, 105(3):1337-1342.
46. Iolascon A., d'Apolito M., Servedio V., Cimmino F., Piga A., Camaschella C. Microcytic anemia and hepatic iron overload in a child with compound heterozygous mutations in DMT1 (SCL11A2). Blood 2006, 107(1):349-354.
47. Beaumont C., Delaunay J., Hetet G., Grandchamp B., de Montalembert M., Tchernia G. Two new human DMT1 gene mutations in a patient with microcytic anemia, low ferritinemia, and liver iron overload. Blood 2006, 107(10):4168-4170.
48. De Falco L., Bruno M., Andolfo I., et al. Identification and characterization of the first SLC11A2 isoform 1a mutation causing a defect in splicing process and an hypomorphic allele expression of the SLC11A2 gene. Br J Haematol 2012, 159(4):492-495.
49. Iolascon A., Camaschella C., Pospisilova D., Piscopo C., Tchernia G., Beaumont C. Natural history of recessive inheritance of DMT1 mutations. J Pediatr 2008, 152:136-139.
50. Horvathova M., Kapralova K., Zidova Z., Dolezal D., Pospisilova D., Divoky V. Erythropoietin driven signaling ameliorates the survival defect of DMT1-mutant erythroid progenitors and erythroblasts. Haematologica 2012, 97(10):1480-1488.
51. De Falco L., Sanchez M., Silvestri L., et al. Iron refractory iron deficiency anemia. Haematologica 2013, 98(6):845-853.
52. Finberg K.E., Heeney M.M., Campagna D.R., et al. Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nat Genet 2008, 40(5):569-571.
53. Silvestri L., Pagani A., Nai A., De Domenico I., Kaplan J., Camaschella C. The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin. Cell Metab 2008, 8(6):502-511.
54. De Falco L., Silvestri L., Kannengiesser C., et al. Functional and clinical impact of novel TMPRSS6 variants in iron-refractory iron-deficiency anemia patients and genotype-phenotype studies. Hum Mutat 2014, 35(11):1321-1329.
55. Grandchamp B., Hetet G., Kannengiesser C. A novel type of congenital hypochromic anemia associated with a nonsense mutation in the STEAP3/TSAP6 gene. Blood 2011, 118(25):6660-6666.
56. Baker R.D. Zinc protoporphyrin to prevent iron deficiency. JAMA Pediatr 2013, 167(4):393-394.
57. St Pierre T.G., Clark P.R., Chua-anusorn W., et al. Non invasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 2005, 105(2):855-861.
58. Castagna A., Campostrini N., Zaninotto F., Girelli D. Hepcidin assay in serum by SELDI-TOF-MS and other approaches. J Proteomics 2010, 73(3):527-536.
59. Bozzini C., Campostrini N., Trombini P., et al. Measurement of urinary hepcidin levels by SELDI-TOF-MS in HFE-hemochromatosis. Blood Cells Mol Dis 2008, 40(3):347-352.
60. Ganz T., Olbina G., Girelli D., Nemeth E., Westerman M. Immunoassay for human serum hepcidin. Blood 2008, 112(10):4292-4297.